Literature DB >> 7125890

Indications for therapy for fungemia in postoperative patients.

J S Solomkin, A M Flohr, R L Simmons.   

Abstract

We reviewed the clinical courses of 63 surgical patients who had experienced one or more days of fungemia, to determine the clinical setting for such infections and to define indications for systemic therapy. Fifty-one patients experienced fungemia as a late complication of intraperitoneal infection. Candida was identified as part of a polymicrobial flora in 70%. If untreated, the mortality was 83% (30 of 36). No untreated patients with fungemia for more than one day survived. Adequate therapy with amphotericin B (total dose, greater than 3 mg/kg) improved survival to 67% (ten of 15). Autopsies performed in 20 cases revealed visceral Candida microabscesses in seven, with the gastrointestinal tract (12) and intraabdominal abscess (five) as the most common sources of fungi. These data support the concept of Candida as an important participant in polymicrobial infection and recommend therapy with amphotericin B for patients with intraperitoneal infection experiencing fungemia.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7125890     DOI: 10.1001/archsurg.1982.01380340008003

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  10 in total

1.  Canadian clinical practice guidelines for invasive candidiasis in adults.

Authors:  Eric J Bow; Gerald Evans; Jeff Fuller; Michel Laverdière; Coleman Rotstein; Robert Rennie; Stephen D Shafran; Don Sheppard; Sylvie Carle; Peter Phillips; Donald C Vinh
Journal:  Can J Infect Dis Med Microbiol       Date:  2010       Impact factor: 2.471

2.  Early presumptive therapy with fluconazole for occult Candida infection after gastrointestinal surgery.

Authors:  Yan-Shen Shan; Edgar D Sy; Shan-Tair Wang; Jenq-Chang Lee; Pin-Wen Lin
Journal:  World J Surg       Date:  2006-01       Impact factor: 3.352

3.  Impact of the order of initiation of fluconazole and amphotericin B in sequential or combination therapy on killing of Candida albicans in vitro and in a rabbit model of endocarditis and pyelonephritis.

Authors:  A Louie; P Kaw; P Banerjee; W Liu; G Chen; M H Miller
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

4.  Pharmacodynamics of fluconazole in a murine model of systemic candidiasis.

Authors:  A Louie; G L Drusano; P Banerjee; Q F Liu; W Liu; P Kaw; M Shayegani; H Taber; M H Miller
Journal:  Antimicrob Agents Chemother       Date:  1998-05       Impact factor: 5.191

5.  Invasive candidiasis: comparison of management choices by infectious disease and critical care specialists.

Authors:  Philippe Eggimann; Thierry Calandra; Ursula Fluckiger; Jacques Bille; Jorge Garbino; Michel-Pierre Glauser; Oscar Marchetti; Christian Ruef; Martin Täuber; Didier Pittet
Journal:  Intensive Care Med       Date:  2005-09-20       Impact factor: 17.440

Review 6.  Mycotic infection and the pediatric surgeon.

Authors:  H Nagar
Journal:  Mycopathologia       Date:  1990-12       Impact factor: 2.574

Review 7.  Candida colonization index and subsequent infection in critically ill surgical patients: 20 years later.

Authors:  Philippe Eggimann; Didier Pittet
Journal:  Intensive Care Med       Date:  2014-06-17       Impact factor: 17.440

Review 8.  Antifungal prophylaxis and pre-emptive therapy.

Authors:  Claudio Viscoli
Journal:  Drugs       Date:  2009       Impact factor: 9.546

9.  Candida colonization and subsequent infections in critically ill surgical patients.

Authors:  D Pittet; M Monod; P M Suter; E Frenk; R Auckenthaler
Journal:  Ann Surg       Date:  1994-12       Impact factor: 12.969

Review 10.  Clinical implications of positive blood cultures.

Authors:  C S Bryan
Journal:  Clin Microbiol Rev       Date:  1989-10       Impact factor: 26.132

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.